Survey on Long-Term Use of ORENCIA® Intravenous Infusion 250mg

Bristol-Myers Squibb (BMS)

Status: Completed

Conditions: Rheumatoid Arthritis

Treatments: Drug: Orencia

Study type: Observational

Funder types: Industry

Identifiers

NCT02600468

IM101-516

Details and patient eligibility

About

The purpose of this study to collect information on the safety, especially serious infections and malignancies, and efficacy of the long-term use of ORENCIA Intravenous Infusion 250mg in patients with rheumatoid arthritis.

Enrollment: 671 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• Patients who are beginning to receive the treatment with ORENCIA Intravenous Infusion 250mg under the approved indications, dosage, and administration
• Have available HAQ data
• Have available DAS28-ESR or DAS28- CRP data
• Have no past or present history of malignancies
• Are expected to be followed up for 3 years

Trial design

671 participants in 1 patient group

Patients who use ORENCIA

Description:

Patients who use ORENCIA for the approved indications and who at the start of treatment

Treatment:

Drug: Orencia